Unfortunately, the monotherapy trials with triciribine of tumors characterized by high Akt activation were not further pursued as they revealed insufficient antitumor activity besides high incidences of hepatotoxicity, hypertriglyceridemia, thrombocytopenia, and hyperglycemia as adverse effects [28]. This evidence concerns the gene AKT1 and hypertriglyceridemia.